Karen Akinsanya - Aug 16, 2021 Form 4 Insider Report for Schrodinger, Inc. (SDGR)

Role
EVP, Chief Biomedical Scientist, Head of Discovery R&D
Signature
/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
Stock symbol
SDGR
Transactions as of
Aug 16, 2021
Transactions value $
-$1,775,022
Form type
4
Date filed
8/17/2021, 05:00 PM
Previous filing
Jun 9, 2021
Next filing
Sep 16, 2021

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SDGR Stock Option (right to buy) Options Exercise $0 -20.2K -10.06% $0.00 180K Aug 16, 2021 Common Stock 20.2K $17.00 Direct F1, F4
transaction SDGR Stock Option (right to buy) Options Exercise $0 -4.18K -8.33% $0.00 46K Aug 16, 2021 Common Stock 4.18K $4.34 Direct F1, F5
transaction SDGR Stock Option (right to buy) Options Exercise $0 -13.4K -50% $0.00 13.4K Aug 16, 2021 Common Stock 13.4K $3.22 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.90 to $57.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (3) of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.905 to $58.86, inclusive.
F4 This option was granted on February 5, 2020. The shares underlying the option vested with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024.
F5 This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.
F6 The option was granted on August 3, 2018. The shares underlying the option are scheduled to vest in equal yearly installments from May 14, 2018 through May 14, 2022.

Remarks:

EVP, Chief Biomedical Scientist, Head of Discovery R&D